Tue, 04 Oct 2022

NEW YORK, NY / ACCESSWIRE / September 21, 2022 / Rosen Law Firm PA:

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ:BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.

Rosen Law Firm PA, Wednesday, September 21, 2022, Press release picture

SO WHAT: If you purchased Blueprint Medicines securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=8186 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On August 17, 2022, before trading hours, Blueprint Medicines announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) in patients with non-advanced systemic mastocytosis (SM). The results showed a deterioration in the absolute improvement in the symptom score from 15.6 points in this most recent trial versus 19.7 in Phase 1.

On this news, Blueprint Medicine' share price fell $7.38 per share, or 10%, to close at $61.17 per share on August 17, 2022, on unusually heavy trading volume.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm PA



View source version on accesswire.com:
https://www.accesswire.com/716957/ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-Blueprint-Medicines-Corporation-Investors-to-Inquire-About-Class-Action-Investigation--BPMC

Sign up for Silicon Valley News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!